Quick Dispatch:
Your tirzepatide surpass trials Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass trials Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program ships.
Need Help?
Questions about tirzepatide surpass trials Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass trials Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program in your area.
01443-4/asset/63fe4912-d57e-4c87-ad6b-1952000f93e1/main.assets/gr1_lrg.jpg)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
23.58
New Dual Incretin Agonist for Type 2 Diabetes
28.96
Media Centre
29.49
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program | Cardiovascular Diabetology
27.25
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
28.70
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized
21.01
Annals
23.45
